Background-We evaluated the viability of I Kur as a target for maintenance of sinus rhythm in patients with a history of atrial fibrillation through the testing of MK-0448, a novel I Kur inhibitor. Methods and Results-In vitro MK-0448 studies demonstrated strong inhibition of I Kur with minimal off-target activity. In vivo MK-0448 studies in normal anesthetized dogs demonstrated significant prolongation of the atrial refractory period compared with vehicle controls without affecting the ventricular refractory period. In studies of a conscious dog heart failure model, sustained atrial fibrillation was terminated with bolus intravenous MK-0448 doses of 0.03 and 0.1 mg/kg. These data led to a 2-part first-in-human study: Part I evaluated safety and pharmacokinetics, and part II was an invasive electrophysiological study in healthy subjects. MK-0448 was well-tolerated with mild adverse experiences, most commonly irritation at the injection site. During the electrophysiological study, ascending doses of MK-0448 were administered, but no increases in atrial or ventricular refractoriness were detected, despite achieving plasma concentrations in excess of 2 μmol/L. Follow-up studies in normal anesthetized dogs designed to assess the influence of autonomic tone demonstrated that prolongation of atrial refractoriness with MK-0448 was markedly attenuated in the presence of vagal nerve simulation, suggesting that the effects of I Kur blockade on atrial repolarization may be negated by enhanced parasympathetic neural tone. Conclusions-The contribution of I Kur to human atrial electrophysiology is less prominent than in preclinical models and therefore is likely to be of limited therapeutic value for the prevention of atrial fibrillation. (Circ Arrhythm Electrophysiol. 2012;5:1193-1201.)
A trial fibrillation (AF), the most common sustained cardiac arrhythmia, is associated with considerable morbidity, as well as mortality. [1] [2] [3] This condition may be effectively managed by either rhythm control (cardioversion) or rate control, depending on the patient profile. For patients who are appropriate candidates for cardioversion, there are several strategies for conversion of AF to sinus rhythm, including electric or pharmacological methods. 4 
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Currently available pharmacotherapies include flecainide, propafenone, amiodarone, and ibutilide, which are sodium channel blockers that block sodium ion channel proteins such as Na v 1.5 and potassium channel blockers that block the rapidly activating delayed rectifier cardiac potassium current (I Kr ) and the slowly activating delayed rectifier cardiac potassium current (I Ks ). 5, 6 Although these agents have modest efficacy in restoring sinus rhythm, they also have unwanted effects on ventricular depolarization (QRS widening caused by slowed conduction) and repolarization (QT-interval prolongation), which may lead to ventricular arrhythmias, such as ventricular tachycardia or torsade de pointes, particularly in patients with structural heart disease. 4, 7, 8 As a result of the risk of these serious adverse effects, a more targeted approach to therapy is an important goal. 8 I Kur is an ultrarapid delayed rectifier current that is different from other currents such as I Kr because of its presence in atrial myocytes and absence in ventricular tissue. 9 Blockade of I Kur has been shown to selectively prolong atrial refractoriness without affecting ventricular repolarization and seems to be an effective antiarrhythmic strategy for the acute conversion of AF in animal models. 10 For these reasons, I Kur blockade may represent an atrial-specific strategy that can lead to therapies that are effective in converting AF, yet do not have ventricular effects. However, research into this target has led to contradictory evidence, suggesting that suppression of I Kur in certain circumstances may promote rather than prevent AF. A loss-of-function mutation in KCNA5, the gene that encodes Kv1.5 channels responsible for I Kur , has been described in a familial case of AF. 11 In isolated human atrial myocytes, exposure to 4-aminopyridine at concentrations reported to selectively block I Kur resulted in action potential prolongation, a propensity to elicit early afterdepolarizations and triggered activity with coexposure to isoproterenol. 11 Similarly in normal mice, the intraperitoneal administration of 4-aminopyridine provoked premature atrial complexes, with AF induced by coadministration of isoproterenol. 11 Furthermore, experimental evidence has shown that exposure to 4-aminopyridine allowed induction of AF in healthy isolated canine coronary-perfused right atrial preparations and failed to terminate fibrillation in remodeled atrial preparations. 12 Data from Wettwer et al 13 suggest that whether inhibition of I Kur prolongs or shortens action potential duration depends on the disease status of the atria and is determined by the level of electric remodeling. They concluded that I Kur blockade shortens action potential duration at 90% in sinus rhythm but prolongs it in AF. This is probably because of the observation that normal (healthy) atria typically displayed action potentials with a prominent plateau, whereas remodeled atria displayed triangular-shaped action potentials. 12 We developed MK-0448
to test the hypothesis that specific blockade of I Kur would be an effective pharmacological approach for the termination and prevention of AF without the ventricular effects that are associated with other antiarrhythmics. MK-0448 is an agent that is structurally related to triarylethanolamine, 2-phenyl-1,1-dipyridin-3-yl-2-pyrrolidin-1-yl-ethanol, a probe compound demonstrated to have atrial specificity and antiarrhythmic activity in an animal model of AF. 10 Triarylethanolamine, 2-phenyl-1,1-dipyridin-3-yl-2-pyrrolidin-1-yl-ethanol was the basis for MK-0448, which was generated to optimize various pharmacokinetic properties while maintaining specificity for Kv1.5, a potassium channel that is responsible for I Kur.
14 In addition, isoquinolinone-1, a structurally distinct compound that also targets Kv1.5, was also previously shown to be significantly more effective in terminating AF than placebo in a dog heart failure AF model. 10 We conducted in vitro and in vivo studies, as well as first-in-human (FIH) studies with electrophysiological (EP) testing using MK-0448, to examine whether blockade of Kv1.5 (and hence I Kur ) would increase atrial refractoriness and thereby demonstrate potential as a treatment for AF in humans.
Methods

Preclinical Program
Detailed methodologies for preclinical in vitro studies are provided in online-only Data Supplement Appendix I. Presented here is a summary of methods for the in vitro and in vivo studies.
In Vitro Studies
Inhibition of currents carried by heterologously expressed Kv1.5 and native I Kur channels was assessed using Chinese hamster ovary cells and human atrial myocytes, respectively, in functional voltage-clamp assays with traditional patch-clamp EP methods to determine potency. Ventricular repolarization was studied by testing effects on human ether-a-go-go gene channels heterologously expressed in Chinese hamster ovary-K1 cells using standard whole-cell voltage-clamp techniques. Current amplitudes recorded predrug and postdrug were compared pairwise to determine the inhibitory effect. The percent inhibition of the peak control current was plotted as a function of compound concentration, and the concentration of drug required to inhibit current by 50% (IC 50 ) was determined by fitting the Hill equation to the concentration response data: percentage of control=100×(1+([drug]/ IC 50 ) p ) −1 . We also tested effects on slowly activating cardiac delayed rectifier K + current, I Ks , resulting from the stable coexpression of the ion channel subunits hKCNQ1 and hKCNE1 in human embryonic kidney-293 host cell line. Specific assays for I K1 , I to , I Na , Kv3.2, IK Ca , Kv2.1, Kv1.7, and NR1a/2B were also performed.
In Vivo Studies
Cardiac EP Studies in Anesthetized Dogs
The electrocardiographic and cardiac EP effects of MK-0448 were compared with vehicle-matched control infusions in anesthetized male or female mongrel dogs (6.3-12.1 kg). The surgical preparation and methods for the measurement of cardiac EP parameters in anesthetized dogs were as described previously. 15 Dogs were anesthetized with αchloralose (100 mg/kg IV) and minimal sodium pentobarbital (5 mg/ kg IV) to provide additional analgesia and anesthesia. A continuous infusion of α-chloralose (10 mg/kg per hour IV) was used to maintain anesthesia during the time course of the study. 15 At 30 minutes after surgical preparation, the following parameters were measured before (baseline) and at 15, 30, 45, and 60 minutes after initiation of 60 minutes of continuous intravenous infusions of vehicle or test agent: sinus heart rate, mean arterial pressure, ECG intervals including rate-corrected QT interval [(QT in ms)/√(R-R in seconds)], atrial excitation threshold and ventricular excitation threshold, and atrial and ventricular relative refractory periods (ARRP, VRRP). ARRP and VRRP are commonly used measures of refractory period in intact animal cardiac electrophysiology studies 10, 15 ; in this study, they were determined using programmed pacing at a basic S1-S1 cycle length of 400 ms (150 beats per minute), introducing S2 at 2×ET and decrementing the S1-S2 initially at 10-ms intervals followed by 2-ms intervals until an S2 extrastimulus could not be propagated. Blood samples for determination of plasma concentrations of MK-0448 by liquid chromatographytandem mass spectrometry were also obtained at these time points.
Two temporally distinct sets of in vivo cardiac EP studies were conducted. Lower dose range studies were conducted to determine the pharmacologically effective dose/plasma concentration of MK-0448 and consisted of 4 groups of dogs assigned to intravenous treatment with vehicle (25% hydroxypropyl-β-cyclodextrin aqueous; n=6) or MK-0448 at 0.15 (n=4), 0.30 (n=5), or 0.45 µg/kg per minute (n=5) infused at a rate of 20 mL/h. Subsequently, higher dose range studies were conducted, consisting of 3 groups of dogs assigned to intravenous treatment with vehicle (25% hydroxypropyl-β-cyclodextrin aqueous; n=2) or MK-0448 at 20.0 (n=4) or 30.0 µg/kg per minute (n=4) infused at a rate of 20 mL/h.
EP Study of AF in a Dog Heart Failure Model
The surgical preparation and methods for the production of heart failure by rapid right ventricular pacing, as well as cardiac EP testing and induction of AF by atrial burst pacing, are previously described. 10 In these 3 animals, MK-0448 dosing was initiated after 15 minutes of sustained AF. MK-0448 was administered as 30-second intravenous infusions at 5-minute intervals at sequential doses of 0.03, 0.1, 0.3, and 1.0 mg/kg. Blood samples were drawn before dosing, at termination of AF, or at 5 minutes after the highest dose tested if AF was not terminated.
FIH Study
The FIH study (Sponsor Protocol 001) was conducted from August 2005 to February 2006 following approval by the Thomas Jefferson University Investigational Review Board and the Thomas Jefferson University Hospital and Clinical Pharmacology Unit and was conducted in accordance with Good Clinical Practice principles. Before enrollment, all patients provided written informed consent.
This was a 2-part study. Part I was done to evaluate the safety and tolerability of intravenous doses of MK-0448, to obtain pharmacokinetic parameters, and to evaluate urinary excretion and pharmacodynamic effects on heart rate, blood pressure, and ECG parameters. Part II used novel techniques to evaluate the EP effects of MK-0448 on atrial and ventricular refractory period duration, as well as sinus node, atrioventricular node, and His-Purkinje function.
Part I was a double-blind, randomized, placebo-controlled, multiple-period, alternating panel, rising-dose study in healthy male subjects. Two panels (panels A and B) consisting of 8 subjects each alternatively received single intravenous rising infusions of MK-0448 or matching placebo in a 3:1 ratio, respectively, in up to 5 treatment periods. Doses for panel A were 0.5, 2, 8, 18, and 32 mg for each successive period. Doses for panel B were 1, 4, 12, 24, and 40 mg for each successive period. At least 3 days elapsed before administration of the next higher dose. All doses were administered for 2 hours (sterile solution of 0.1 mg/mL IV in a 50-mL vial).
An additional serial panel (panel C) was conducted after a satisfactory evaluation of safety, tolerability, and preliminary pharmacokinetic data from all doses administered in panels A and B. Panel C (8 subjects: 6 active and 2 placebo) was administered as single intravenous infusions for 2 hours in a 5-period single ascending-dose design with doses at 40, 50, 62, 80, and 100 mg for each successive period.
Safety measures included telemetry monitoring, 12-lead ECGs, physical examinations, and vital signs, including measurement of orthostatic heart rate and blood pressure. During and after infusions of MK-0448, specimens were obtained for pharmacokinetic analysis.
Part II was a placebo-controlled, rising, single-dose study in healthy male subjects (panel D). Electrophysiology studies were performed after overnight fasting. Caffeinated beverages and tobacco use were not allowed during the study period. The starting dose for part II was selected to target a concentration at the end of infusion (C eoi ) of 100 nmol/L based on the pharmacokinetic data from part I and was expected to be ≈2 mg delivered over 2 hours, based on allometric scaling of pharmacokinetic data from preclinical experiments. Each subject had 3 venous sheaths placed percutaneously in the femoral veins after infiltration of lidocaine without epinephrine. None of the subjects received systemic anesthetics or sedation during the procedure. Through those sheaths, quadripolar catheters were advanced into the heart under fluoroscopic guidance using the standard procedures and techniques that have been established for clinical electrophysiology studies. Blood pressure was monitored every 10 minutes with an inflatable cuff on the upper arm. The 3 catheters were placed in the right atrium, in the region of the His bundle, and in the right ventricle. Placement was confirmed fluoroscopically and with continuous monitoring of the intracardiac electrograms. After a 15-minute baseline period, sinus node recovery times, atrial effective refractory period (AERP), atrioventricular node refractoriness and Wenckebach cycle length, His-Purkinje reserve, and ventricular effective refractory period (VERP) were measured. Standard protocols for programmed electric stimulation were used. Pacing was performed at twice diastolic threshold. AERP measurements were performed from the high right atrial location at 2 drive cycle lengths: 600 ms and 400 ms. Premature impulses were delivered after a drive train of 8 impulses. The degree of prematurity was increased (the coupling interval was shortened) in 10-ms decrements until failure to capture was noted on 2 consecutive runs. Ventricular programmed stimulation was performed in the exact same fashion from the right ventricular apex.
After the initiation of the intravenous infusion of MK-0448 or placebo, sets of atrial and VERP measurements were made every 20 minutes. After each set of effective refractory period measurements, pharmacokinetic samples were obtained from the side ports of the femoral venous sheaths. At the end of the 2-hour infusion, measurements of sinus node recovery times, AERP, atrioventricular node refractoriness and Wenckebach cycle length, His-Purkinje reserve, and VERP were repeated. In the hour after the discontinuation of the infusion, additional sets of AERP and VERP measurements were made every 20 minutes, along with pharmacokinetic sampling. The catheters were then removed, the venous sheaths were removed, hemostasis was attained by manual compression, and the subjects were transported back to the Clinical Research Unit where they were monitored overnight.
Confirmatory In Vivo Studies in Dogs: Atrial Refractoriness in Anesthetized Dogs With Vagal Nerve Stimulation
A follow-up study in anesthetized dogs was specifically designed to assess the influence of autonomic tone on the effects of MK-0448 on atrial refractoriness. To control autonomic status in the present study, the α-chloralose/pentobarbital anesthetic regimen used in the previous cardiac EP study in dogs was replaced with an α-chloralose/morphine regimen to preclude effects of pentobarbital on vagal tone, and nadolol was administered to control sympathetic tone. Mongrel dogs (male or female, 6.7-12.0 kg) were anesthetized with α-chloralose (100 mg/kg IV) and morphine (2 mg/kg IM) and ventilated with room air via an endotracheal tube. The left and right femoral veins were cannulated for blood sampling and treatment infusion, and the left femoral artery was cannulated for blood pressure monitoring. Pin electrodes were attached for the monitoring of lead II ECG. Both cervical vagal nerve trunks were isolated and ligated rostrally. Bipolar hook electrodes composed of 0.25-mm-diameter Teflon-coated silver wire, with insulation removed at the terminal 1 to 2 mm, were inserted into the middle of each vagal nerve by means of 18-gauge hypodermic needles. The vagal nerve electrodes were advanced caudally within and parallel to vagal fibers for several centimeters. A left thoracotomy was performed at the fourth intercostal space, and the heart was exposed after pericardial incision and cradled. A stainless steel epicardial bipolar electrode was sutured to the right atrium for pacing, and a stainless steel epicardial quadripolar electrode was sutured to the left atrium for sensing left atrial electrograms and for the determination of atrial excitation threshold and ARRP (2-ms pulse duration, 2× atrial excitation threshold, 150 beats per minute pacing rate). After surgical preparation, a bolus dose of 0.5 mg/kg nadolol IV was administered, and the preparation was allowed to equilibrate for 20 minutes.
At 30 minutes after surgical preparation, animals were randomized to intravenous treatment infusion with either vehicle alone (n=4; 25% aqueous hydroxypropyl-β-cyclodextrin, 10 mL infused over 30 minutes) or 1.0 μg/kg per minute MK-0448 administered in identical vehicle and infusion rate (n=4; in vehicle of 25% aqueous hydroxypropyl-β-cyclodextrin, 10 mL infused over 30 minutes). Based on previous studies with MK-0448 in chloralose/pentobarbital-anesthetized dogs, the 1.0 μg/kg per minute IV infusion was expected to elicit a robust increase in atrial refractory period in the absence of alteration in autonomic tone. The following measurements were obtained at baseline (pretreatment) and at 15 and 30 minutes of treatment infusion: heart rate, lead II ECG intervals including QTc using the Bazett formula, atrial excitation threshold, and ARRP. At each time point in both groups, measurements were obtained sequentially during bilateral vagal stimulation (5.0 V, 0.1-ms pulse duration) at vagal nerve stimulation frequencies of 0 Hz (ie, no vagal pacing), 2 Hz, and 5 Hz. In the MK-0448 treatment groups, blood samples were drawn at baseline (pretreatment) and at 15 and 30 minutes of infusion for the determination of plasma (MK-0448). Changes in ARRP are expressed as percentage changes from baseline within indicated vagal nerve stimulation frequency. (Table 1) .
Results
Specificity
Although MK-0448 strongly blocked I Kur , its effect on other cardiac currents was much weaker, indicating a high degree of selectivity for I Kur . Compared with the low nmol/L range for I Kur , MK-0448 IC 50 values were in the μmol/L range for other cardiac currents, including I Kr (heterologously expressed human ether-a-go-go gene; voltage-clamp IC 50 =110 μmol/L), I TO (heterologously expressed Kv4.3; voltage-clamp IC 50 =2.3 μmol/L), I Na (heterologously expressed SCN5a; inactive up to 10 μmol/L), Kv3.2 (voltage-clamp IC 50 =6.1 μmol/L), and IK Ca (voltage-clamp IC 50 =10.2 μmol/L). Although MK-0448 was generally highly selective against currents expressed in the cardiac ventricles, it did exhibit moderate inhibition of the slowly activating cardiac delayed rectifier K + current, I Ks , with an IC 50 of 0.79 μmol/L (determined by voltage-clamp experiments in human embryonic kidney-293 cells with stable coexpression of the ion channel subunits hKCNQ1 and hKCNE1). Activity against I Ks , however, was seen at a 70-fold higher concentration of MK-0448 than inhibition of I Kur .
Selective Effect of MK-0448 on ARRP in Anesthetized Dogs
Because MK-0448 demonstrated selectivity for I Kur versus ventricular ion channel currents, we investigated whether atrial repolarization might be prolonged preferentially to ventricular repolarization in 3 anesthetized mongrel dogs (2 male and 1 female, 20-26 kg). The effects of MK-0448 were assessed in comparison with vehicle-matched control infusions. Continuous intravenous infusions of MK-0448 at doses of 0.30 and 0.45 μg/kg per minute resulted in exposure-dependent increases in ARRP without changes in VRRP; heart rate; mean arterial pressure; or ECG PR, QRS, and QTc intervals. At a plasma concentration of ≈36 nmol/L, MK-0448 increased ARRP by 10%. In contrast, a mean plasma concentration of ≈6 μmol/L was required to produce changes from baseline of ≈5% in VRRP and QTc. Increases in mean arterial pressure of ≈15 to 20 mm Hg compared with controls were also noted at the elevated plasma concentration of ≈6 μmol/L. Figure 2 shows an integrated pharmacokinetic-pharmacodynamic plot of exposure versus change in ARRP and VRRP from experiments in anesthetized dogs. The vertical dashed lines indicate the magnitude of the window between the exposures that selectively affect the atrium versus exposures that affect both atrium and ventricle. These data indicate that at exposures of MK-0448 that are associated with up to an ≈20% prolongation of ARRP, there is no appreciable effect on ventricular repolarization. These data further suggest that effects on ventricular repolarization are seen at exposures of MK-0448 that are ≈100-fold above those that prolong atrial repolarization.
Effect of MK-0448 on AF in a Dog Heart Failure Model
To directly investigate the antiarrhythmic effects of MK-0448 in the dog model, AF was induced by atrial burst pacing in dogs with heart failure produced by rapid, sustained right ventricular pacing. The cardiac hemodynamic status of these rapid ventricular pacing-induced heart failure dogs has been described previously and was characterized by an increase in left ventricular end diastolic pressure and decreases in left ventricular systolic pressure and +dP/dt. 10 Sustained AF in this model was terminated in 2 of 3 animals tested with intravenous doses of 0.03 mg/kg (termination at 30 seconds after administration) and 0.1 mg/kg MK-0448 (termination at 90 seconds after administration), yielding plasma concentrations of 1.7 and 5.9 μmol/L, respectively, at the times of AF termination (Figure 3 ). In the third animal, AF failed to terminate after the administration of sequential intravenous doses up to 1.0 mg/kg MK-448 on 2 separate study dates, yielding plasma concentrations of 16.9 to 18.7 *n refers to the number of measurements at each concentration tested to define the full concentration response curve and thereby determine the IC50; in cases where n≥3, at least 3 observations were made at each concentration, but commonly it might be more, eg, as many as 6 or 7 at some concentrations, focused on the range between 20% and 80% inhibition, to define the IC50 more precisely. μmol/L at 5 minutes after the final dose. Furthermore, in that series, none of the 7 vehicle-treated controls converted to sinus rhythm. 10 These data suggest that concentrations of MK-0448 that yield significant ARRP prolongation and no or minimal lengthening of VRRP in the dog may be suitable for acute conversion of AF.
Safety, Tolerability, and Pharmacokinetic Findings of MK-0448 in Healthy Young Human Subjects
Given the selectivity of MK-0448 for atrial repolarization and its antiarrhythmic effects in the dog model, MK-0448 was tested in phase I studies for its EP effects in humans. There were 24 healthy male subjects (age range, 23-44 years) who participated in part I of the trial. In part II, there were 6 subjects enrolled. Four subjects discontinued the trial: 1 subject discontinued because of a benign accelerated idioventricular rhythm, 1 subject withdrew for personal reasons, and another subject was lost to follow-up. An additional subject discontinued part II because of an adverse experience of AF that occurred during baseline programmed electric stimulation before dosing.
Online-only Data Supplement Tables I and II and onlineonly Data Supplement Appendix II show adverse experiences for part I and part II, respectively. There were no serious adverse experiences. All adverse experiences were transient and mild in intensity. The most common adverse experience was irritation at the site of injection. Mean area under the curve 0-∞ and concentration at the end of the infusion (C eoi ) seem to increase proportionally with dose through 100 mg to maximal values of 22 904 nmol/L·h and 5726 nmol/L, respectively (online-only Data Supplement Table III and online-only Data Supplement Appendix II).
EP Effects of MK-0448 in Healthy Young Human Subjects
An invasive EP assessment was incorporated into part II of the study to directly measure the effect of MK-0448 on atrial and ventricular refractory periods. In part II, 5 of the 6 enrolled subjects completed dosing; 1 subject did not dose because of the onset of an AE that occurred before dosing that was unrelated to study medication. The 5 completed subjects were administered ascending doses of up to 32 mg of MK-0448 during a 2-hour infusion. In contrast to expectations, there were no increases in AERP or VERP at any dose of MK-0448 (Table 2; Figure 4 ), despite pharmacokinetic analysis confirming plasma concentrations of up to ≈2.1 μmol/L at the highest administered dose. Results for individual patients in the study are shown in online-only Data Supplement Figure I . Thus, despite preclinical data suggesting that MK-0448 preferentially prolongs atrial repolarization in a heart failure dog model, there was no evidence that MK-0448 influenced atrial (or ventricular) repolarization in healthy human volunteers at concentrations up to 2 μmol/L (corresponding to >50-fold higher concentration than the concentration at which significant AERP prolongation was observed in the dog).
Interaction of MK-0448 and Vagal Nerve Stimulation on Atrial Repolarization in Anesthetized Dogs
Because the human subjects tested in phase I were healthy, young, and presumably had high vagal tone and that heart failure is known to be associated with vagal withdrawal, we hypothesized that vagal stimulation might influence the effect of I Kur blockade on prolongation of atrial repolarization. Accordingly, a follow-up study in anesthetized dogs was specifically designed to assess the influence of autonomic tone and, in particular, vagal nerve stimulation on the effects of MK-0448 on atrial refractoriness. As expected, enhanced parasympathetic neural tone produced by bilateral vagal nerve stimulation in the dog model resulted in vagal stimulationdependent decreases in heart rate and ARRP. In the absence of vagal nerve stimulation, 1.0 μg/kg minute IV MK-0448 produced robust (≈20 ms, 20%) increases in ARRP at both 15 and 30 minutes of infusion. In contrast, increases in ARRP in the MK-0448 group during both 2-and 5-Hz vagal nerve stimulation were diminished markedly compared with the absence of vagal stimulation, such that during 2-and 5-Hz vagal nerve stimulation, increases in ARRP were comparable in the MK-0448 and vehicle treatment groups. Figure 5 compares percent changes in ARRP from baseline in the vehicle and MK-0448 treatment groups, respectively, at 30 minutes of treatment infusion. In the vehicle treatment group, only slight increases in ARRP were observed during the duration of the study both in the absence and in the presence of vagal nerve stimulation. Overall, these data suggest that the effect of I Kur blockade on atrial repolarization is exquisitely sensitive to vagal stimulation and may be completely abolished in the setting of enhanced parasympathetic neural tone.
Discussion
The management of AF involves the choice of rate control or rhythm control. 4 Clinical trials have demonstrated that for many antiarrhythmic agents, rhythm control does not confer outcome benefits over rate control, [16] [17] [18] [19] [20] but these observations are likely caused by poor efficacy and toxicity associated with currently available rhythm control options. 17 The challenge presented to researchers is to develop treatments that restore and maintain normal sinus rhythm without the complications that limit widespread use of the currently available methods. In the search for pharmacological mechanisms that are selective and therefore offer greater safety and tolerability compared with available treatments, I Kur blockade is among the most investigated. 8 Several small-molecule agents that block I Kur have been in development and have been tested in preclinical settings. 21, 22 In this study, we investigated whether specific inhibition of I Kur might impact on human atrial EP properties and hence represent a potential therapeutic target for the prevention of AF.
In preclinical studies, MK-0448 demonstrated a selective inhibition of Kv1.5, the major pore-forming subunit of the native cardiac atrial repolarizing current, I Kur , which is expressed in human atrial tissue but not in ventricular tissue. This finding is a significant achievement, considering that the targets of available therapies, which include I Kr and I Ks , are expressed in ventricular as well as atrial tissue, and thus impact on ventricular refractoriness at therapeutic exposures.
Preclinical studies established a relatively high selectivity for I Kur versus other cardiac channels; although moderate inhibition of I Ks was detected, there seems to be a 30-to 100-fold window in preclinical experiments between exposures that have a significant and potentially therapeutic effect on atrial refractoriness and exposures that are associated with small but measurable changes in ventricular refractoriness. Preclinical in vivo experiments demonstrated selectivity for increasing atrial refractory period at plasma concentrations far below those at which changes in ventricular refractory period were observed. Furthermore, studies in conscious dogs with sustained AF in the setting of heart failure demonstrated that AF terminated in 2 of 3 dogs after intravenous administration of MK-0448.
Based on preclinical results demonstrating a selective increase in atrial refractory period, we conducted human studies of MK-0448 to determine safety tolerability, pharmacokinetics, and effects on atrial and ventricular electrophysiology. Although invasive techniques are not common in FIH settings, this approach allowed for determination of whether MK-0448 had any target effect in the atria, if there is a ventricular effect, and to help guide dose selection for future studies. Indeed, we found only one other study that performed invasive diagnostic electrophysiology evaluation in 23 healthy volunteers. 23 That study also included placement of an intra-arterial catheter for blood pressure monitoring, and the authors did not report on any complications.
MK-0448 was generally well-tolerated in our FIH study. However, no increase in atrial or ventricular refractory period was observed, despite pharmacological confirmation of exposure. These results were not expected, given the atrial effects observed in preclinical studies. One possible explanation for the difference in preclinical and clinical effects on atrial refractoriness is that elevated vagal tone in the young healthy patients included in the study may have masked or diminished the role of I Kur in atrial repolarization, whereas the preclinical data were obtained in a heart failure model. Although tests to definitively determine high vagal tone for the volunteers in this study were not done, the following observations can be made: the subjects were all 23 to 44 years of age and generally healthy, characteristics that are reliably consistent with high vagal tone 24 ; marked respirophasic sinus arrhythmia was noted in all subjects during the EP study, which is a well-known marker of preserved vagal tone. 25, 26 To examine the possibility that high vagal tone had an effect on our results, we conducted a follow-up study of atrial refractoriness in anesthetized dogs (without heart failure) in the absence and presence of bilateral vagal nerve stimulation. Although healthy conscious resting dogs have high vagal tone, our invasive electrophysiology study was performed in anesthetized dogs. In the absence of vagal nerve stimulation, MK-0448 administration resulted in an increase in atrial refractory period, as observed in previous preclinical experiments. In the presence of vagal nerve stimulation, however, increases in atrial refractory period were greatly attenuated. These results suggest that I Kur blockade by MK-0448 is diminished with enhanced parasympathetic neural tone. The mechanism whereby enhanced vagal tone ameliorates the effect of I Kur blockade on refractory period may involve a shortening of the atrial action potential duration as a result of increasing I KACh . 27 Conversely, it is also possible that MK-0448 is most effective in the presence of enhanced sympathetic tone, as seen in heart failure.
Loss of I Kur blockade by MK-0448 in states of enhanced vagal tone presents a challenge for maintaining therapeutic efficacy, given the purported profibrillatory effects of vagal stimulation. In the dog model, vagal stimulation shortens the AERP in a nonhomogeneous manner 28 so that under states of high vagal tone, the atria demonstrate inhomogeneity of refractoriness. In this milieu, premature impulses will fractionate or propagate nonuniformly, setting up reentrant rotors that initiate AF. Withdrawal of vagal tone will often result in cessation of AF in the dog model. 29
Limitations
Important limitations of this study are that confounding influences, including sympathetic tone, age, and species differences, may account for differences between results in dog and human experiments. Indeed there is substantial variability in parameters tested not only between species but also within species. It is noteworthy that in the full series of heart failure animals with sustained AF tested with 2 prototype I Kur blockers triarylethanolamine, 2-phenyl-1,1-dipyridin-3-yl-2-pyrrolidin-1-yl-ethanol and isoquinolinone-1, the I KUR blocker MK-499, and the class IC antiarrhythmic agent propafenone, no test agent was found to be universally effective in terminating AF in all animals tested, suggesting animal-to-animal differences in substrate for AF. Thus, the limited numbers of animals tested in this study may have initially given the impression that MK-0448 may have effectively suppressed AF. In addition, our FIH study included young, healthy volunteers, a population that is unlikely to develop AF. Although lone AF can occur in younger patients without associated heart disease (often associated with high vagal tone), this is almost invariably a benign and self-terminating arrhythmia. The majority of AF occurs in older patients with coexisting heart disease (hypertension, cardiomyopathy, heart failure, valvular lesions, following thoracic surgery, etc) and is associated with an elevated risk of stroke. The pathogenesis of these 2 broad categories of AF has diverse mechanisms, and it remains to be proven that a drug that targets a single channel in healthy hearts would have comparable EP and antiarrhythmic effects in diseased hearts.
In summary, extensive preclinical experience with MK-0448 demonstrated that inhibition of I Kur was generally well-tolerated and produced increased atrial refractory period without ventricular effects. This study demonstrated a lack of EP effects of specific blockade of Kv1.5 in healthy human subjects, as evidenced by a lack of significant effect on atrial refractoriness. This may have been because of diminished contribution of I Kur to atrial repolarization in the presence of enhanced parasympathetic tone; alternately, blockade of Kv1.5 by MK-0448 may only be manifest in the setting of enhanced sympathetic tone. This study provides evidence of the feasibility, value, and safety of diagnostic EP studies in healthy volunteers in early clinical assessments of novel compounds. These data suggest that, depending on the conditions of study including autonomic tone, commonly used preclinical models focusing on atrial electrophysiology may lack clinical translatability. Furthermore, targeting I Kur may be of limited therapeutic value for the prevention of AF caused by sensitivity of effect to parasympathetic tone.
